Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.

Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.

His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by Gilead Sciences in March 2024, board member at Oncternal Therapeutics (Nasdaq: ONCT) from 2019 to 2025, and Executive Chairman of GTx Inc. from 2015 to 2019. He previously spent more than 25 years at Johnson & Johnson, where he held roles including Vice President of Alliance Management at the Janssen Pharmaceutical Companies and Senior Vice President of Global Development.

Dr. Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin, and a Ph.D. in Pharmaceutics from the University of Texas.

"He brings a wealth of experience, strategic insight, and a deep understanding of our business," said Michael McFadden, Chief Executive Officer of Alpha Cognition.